000 -LEADER | |
---|---|
fixed length control field | 03725nam a22004575i 4500 |
001 - CONTROL NUMBER | |
control field | 978-3-030-99995-7 |
003 - CONTROL NUMBER IDENTIFIER | |
control field | DE-He213 |
005 - DATE AND TIME OF LATEST TRANSACTION | |
control field | 20240729133802.0 |
007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION | |
fixed length control field | cr nn 008mamaa |
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
fixed length control field | 220721s2022 sz | s |||| 0|eng d |
020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
ISBN | 9783030999957 |
-- | 978-3-030-99995-7 |
072 #7 - SUBJECT CATEGORY CODE | |
Subject category code | MMG |
Source | bicssc |
072 #7 - SUBJECT CATEGORY CODE | |
Subject category code | MED071000 |
Source | bisacsh |
072 #7 - SUBJECT CATEGORY CODE | |
Subject category code | MKG |
Source | thema |
245 10 - TITLE STATEMENT | |
Title | From Obesity to Diabetes |
250 ## - EDITION | |
Edition statement | 1st ed. 2022. |
264 #1 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
Place of production, publication, distribution, manufacture | Cham : |
Name of producer, publisher, distributor, manufacturer | Springer International Publishing : |
-- | Imprint: Springer, |
Date of production, publication, distribution, manufacture, or copyright notice | 2022. |
300 ## - PHYSICAL DESCRIPTION | |
Physical description | VIII, 513 p. 1 illus. |
Other physical details | online resource. |
336 ## - CONTENT TYPE | |
Content type term | text |
Content type code | txt |
Source | rdacontent |
337 ## - MEDIA TYPE | |
Media type term | computer |
Media type code | c |
Source | rdamedia |
338 ## - CARRIER TYPE | |
Carrier type term | online resource |
Carrier type code | cr |
Source | rdacarrier |
490 1# - SERIES TITLE | |
Series statement | Handbook of Experimental Pharmacology, |
International Standard Serial Number | 1865-0325 ; |
Volume | 274 |
505 0# - CONTENTS | |
Contents | Part I Obesity. Epidemiology of Obesity -- The Circadian Clock and Obesity -- Nutrition and Microbiome -- From Obesity to Diabetes: The Role of the Adipose Organ -- Targeting Epicardial Fat in Obesity and Diabetes Pharmacotherapy -- The Enteroendocrine System in Obesity -- Insights from Studies of White Adipose Tissue Using Single-Cell Approaches -- Obesity-Related Insulin Resistance: The Central Role of Adipose Tissue Dysfunction -- Obesity, Senescence, and Senolytics -- Obesity and Obstructive Sleep Apnea -- Part II Diabetes and Complications. Inter-Organ Crosstalk in the Development of Obesity-Associated Insulin Resistance -- Islet Inflammation and β Cell Dysfunction in Type 2 Diabetes -- NAFLD and NASH: The Metabolically Diseased Liver -- Diabetic Kidney Disease: From Pathogenesis to Novel Treatment Possibilities -- Diabetic Peripheral Neuropathy -- Part III Lifestyle Modifications and Future Treatments. Weight Loss Strategies -- PhysicalActivity, Obesity and Weight Loss Maintenance -- Bariatric/Metabolic Surgery -- Drugs for Treating Obesity -- Novel Drugs for Diabetes Therapy -- Novel Approaches to Restore Pancreatic Beta-Cell Mass and Function -- Precision Medicine and Obesity -- Targeting the Enteroendocrine System for Treatment of Obesity. |
520 ## - ABSTRACT | |
Abstract | Obesity is a major risk factor for the development of type 2 diabetes and its associated complications, a major socio-economic burden for health care systems. The worldwide prevalence of obesity doubled since 1980 and as a consequence the number of patients with diabetes has been continuously rising with more than 450 Mio. people suffering from this disease at the present time. Substantial progress has been made in understanding the molecular pathways leading from excessive fat accumulation to metabolic perturbation and finally diabetes manifestation. This edition of the "Handbook of Experimental Pharmacology" aims to analyze new insight into the pathophysiology of obesity, to decipher the complex links to diabetes and its complications, and to collect most recent information on new strategies for prevention and treatment of obesity and diabetes. |
650 #0 - SUBJECT HEADINGS | |
Subject term | Pharmacology. |
9 (RLIN) | 7400 |
650 #0 - SUBJECT HEADINGS | |
Subject term | Metabolism |
General subdivision | Disorders. |
650 14 - SUBJECT HEADINGS | |
Subject term | Pharmacology. |
9 (RLIN) | 7400 |
650 24 - SUBJECT HEADINGS | |
Subject term | Metabolic Disease. |
700 1# - ADDED PERSONAL NAME | |
Added personal author | Eckel, Juergen. |
Relator term | editor. |
700 1# - ADDED PERSONAL NAME | |
Added personal author | Cl�ment, Karine. |
Relator term | editor. |
710 2# - ADDED CORPORATE NAME | |
Added corporate author | SpringerLink (Online service) |
830 #0 - SERIES ADDED ENTRY--UNIFORM TITLE | |
Uniform title | Handbook of Experimental Pharmacology, |
International Standard Serial Number | 1865-0325 ; |
Volume number/sequential designation | 274 |
856 ## - ONLINE RESOURCE | |
Uniform Resource Identifier | <a href="#gotoholdings">#gotoholdings</a> |
Link text | Access resource |
245 ## - TITLE STATEMENT | |
Medium | [E-Book] |
347 ## - DIGITAL FILE CHARACTERISTICS | |
File type | text file |
Encoding format | |
Source | rda |
912 ## - | |
-- | ZDB-2-SBL |
912 ## - | |
-- | ZDB-2-SXB |
Withdrawn status | Lost status | Damaged status | Not for loan | Home library | Current library | Shelving location | Date acquired | Source of acquisition | Total Checkouts | Date last seen | Uniform Resource Identifier | Price effective from | Koha item type |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Hillingdon Hospitals Library Services (Hillingdon Hospitals NHS Foundation) | Hillingdon Hospitals Library Services (Hillingdon Hospitals NHS Foundation) | Online | 02/05/2024 | Springer BiomedLifeSc | 02/05/2024 | https://go.openathens.net/redirector/nhs?url=https://doi.org/10.1007/978-3-030-99995-7 | 02/05/2024 | Electronic book |